{"count": 3, "results": [{"_id": "37409755", "pmid": 37409755, "title": "Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway.", "journal": "Br J Haematol", "authors": ["Hua L", "Yang N", "Li Y", "Huang K", "Jiang X", "Liu F", "Yu Z", "Chen J", "Lai J", "Du J", "Zeng H"], "date": "2023-07-06T00:00:00Z", "doi": "10.1111/bjh.18968", "meta_date_publication": "2023 Jul 6", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50256.992, "text_hl": "In both @CELLLINE_CVCL:2119 @@@Molm13@@@ and @CELLLINE_CVCL:0006 @@@THP-1@@@ cell lines, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @CHEMICAL_venetoclax @CHEMICAL_MESH:C579720 @@@venetoclax@@@ synergistically inhibited the proliferation and induced apoptosis of @<m>DISEASE_Leukemia_T_Cell</m> @DISEASE_MESH:D015458 @@@leukaemia@@@ cells. ", "citations": {"NLM": "Hua L, Yang N, Li Y, Huang K, Jiang X, Liu F, Yu Z, Chen J, Lai J, Du J, Zeng H. Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway. Br J Haematol. 2023 Jul 6;():. PMID: 37409755", "BibTeX": "@article{37409755, title={Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway.}, author={Hua L and Yang N and Li Y and Huang K and Jiang X and Liu F and Yu Z and Chen J and Lai J and Du J and Zeng H}, journal={Br J Haematol}}"}}, {"_id": "35344184", "pmid": 35344184, "title": "Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?", "journal": "Adv Ther", "authors": ["Papachristou S", "Popovic DS", "Papanas N"], "date": "2022-06-01T00:00:00Z", "doi": "10.1007/s12325-022-02125-1", "meta_date_publication": "2022 Jun", "meta_volume": "39", "meta_issue": "6", "meta_pages": "2283-2286", "score": 50246.273, "text_hl": "@DISEASE_Monoclonal_Gammopathy_of_Undetermined_Significance @DISEASE_MESH:D008998 @@@MGUS@@@ may progress to @DISEASE_Myeloproliferative_Disorders @DISEASE_MESH:D009196 @@@myeloproliferative disorders@@@ or @DISEASE_Multiple_Myeloma @DISEASE_MESH:D009101 @@@multiple myeloma@@@, but very little is known about any modifiable risk factors or any preventative treatment that might delay this progression. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ has begun to be discussed as a potentially useful agent on the basis of the results of epidemiological and preclinical research showing that it may be beneficial in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Leukemia_T_Cell</m> @DISEASE_MESH:D015458 @@@leukaemia@@@, @DISEASE_Lymphoma @DISEASE_MESH:D008223 @@@lymphomas@@@ and @DISEASE_Multiple_Myeloma @DISEASE_MESH:D009101 @@@multiple myeloma@@@. ", "citations": {"NLM": "Papachristou S, Popovic DS, Papanas N. Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises? Adv Ther. 2022 Jun;39(6):2283-2286. PMID: 35344184", "BibTeX": "@article{35344184, title={Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?}, author={Papachristou S and Popovic DS and Papanas N}, journal={Adv Ther}, volume={39}, number={6}, pages={2283-2286}}"}}, {"_id": "37354675", "pmid": 37354675, "title": "NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER.", "journal": "Georgian Med News", "authors": ["Tchernev G", "Kordeva S"], "date": "2023-04-01T00:00:00Z", "meta_date_publication": "2023 Apr", "meta_volume": "", "meta_issue": "337", "meta_pages": "63-67", "score": 50218.64, "text_hl": "The newly introduced regulatory norms in practice concern the potential/permissive availability of @CHEMICAL_Nitrosamines @CHEMICAL_MESH:D009602 @@@nitrosamines@@@ in a serious number of drugs: drugs with radically different mechanisms of action such as: @CHEMICAL_Ranitidine @CHEMICAL_MESH:D011899 @@@ranitidine@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, ACE inhibitors, beta blockers, thiazide diuretics, sartans, @CHEMICAL_Rifampin @CHEMICAL_MESH:D012293 @@@rifampicin@@@, but also probably a number of others. ", "citations": {"NLM": "Tchernev G, Kordeva S. NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER. Georgian Med News. 2023 Apr;(337):63-67. PMID: 37354675", "BibTeX": "@article{37354675, title={NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER.}, author={Tchernev G and Kordeva S}, journal={Georgian Med News}, number={337}, pages={63-67}}"}}]}